Norwich Research Park Leadership Session at Genesis 2017- Collaborating with the Microbiome

/in /by

Norwich Research Park Leadership Session at Genesis 2017- Collaborating with the Microbiome
Dec 14, 2017
London

Microbiotica to Participate in Microbiome Panel at BIO-Europe®

/in /by

Cambridge, UK, 25th October 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the Microbiome panel at the 23rd Annual International Partnering Conference, BIO-Europe®, which will be held from 6-8 November, in Berlin, Germany.

The discussion, entitled ‘Targeting the microbiome: From scientific evidence to regulatory approval‘, will take place on 6th November at 2.45 pm.  The panel will discuss the therapeutic potential of this fast-growing field of research and the variety of strategies that companies have to choose from, as well as considering how companies select the best clinical and regulatory pathway for their products.

BIO-Europe® is Europe’s largest life science partnering conference; it provides a forum for companies across the biotech industry to meet and do business, through its range of workshops, exhibitions, panels and one-to-one meetings.

Microbiotica, spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Trevor Lawley and is focused on microbiome biology and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics.

Microbiotica Celebrates Successful First Year with Third Award Win

/in /by

Company receives ‘Best Start-up Biotech’ at OBN Awards

Cambridge, UK, 11 October 2017 – Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces that it has been awarded UK Best Start-up Biotech at the OBN Awards, which took place at Oxford Town Hall.

The award recognises Microbiotica’s commercial potential in the fast-growing microbiome space, reflecting its innovative approach to transforming personalised medicine across therapeutic areas through leading microbiome science.

In 2016, Microbiotica was created with £8m funding from Cambridge Innovation Capital and IP Group to commercialise the ground-breaking research of the Wellcome Trust Sanger Institute.

Mike Romanos, CEO of Microbiotica, said of the win: “We are delighted to have received the recognition of our peers in the UK biotech industry with our third industry award win. We believe this reflects the strength of the science that the Company is based on, the quality of our team and the very rapid progress it has made in the first year.”

The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry.

Microbiotica Wins Biotech and Money’s ‘Life Science Spin-out of the Year’

/in /by

Cambridge, UK, 18 September 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it was chosen as the winner of the ‘Life Science Spin-out of the Year’ at the recent Biotech and Money 2017 Awards.

The award recognises both Microbiotica’s potential in the microbiome sector and its achievements to date as the newest spin-out company from the world-renowned Wellcome Trust Sanger Institute, Cambridge, including its £8m equity financing in 2016 from Cambridge Innovation Capital and IP Group. The Company is at the forefront of understanding how the microbiome can be used to develop new therapeutics for a range of diseases and to stratify patients according to their microbiata.

Votes for each category were determined 50% by advanced online voting and 50% by a live vote on the night of the Awards dinner, which was held in London on 14 September.

Dr Mike Romanos, CEO of Microbiotica, said: “It is rewarding for our team to achieve this recognition in the first year. Being selected for this award by our peers is a great endorsement of the strength of Microbiotica’s science and the progress made by its talented team.”

Microbiotica to Present at Leading Microbiome Summit

/in /by

Cambridge, UK, 18 September 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it was chosen as the winner of the ‘Life Science Spin-out of the Year’ at the recent Biotech and Money 2017 Awards.

The award recognises both Microbiotica’s potential in the microbiome sector and its achievements to date as the newest spin-out company from the world-renowned Wellcome Trust Sanger Institute, Cambridge, including its £8m equity financing in 2016 from Cambridge Innovation Capital and IP Group. The Company is at the forefront of understanding how the microbiome can be used to develop new therapeutics for a range of diseases and to stratify patients according to their microbiata.

Votes for each category were determined 50% by advanced online voting and 50% by a live vote on the night of the Awards dinner, which was held in London on 14 September.

Dr Mike Romanos, CEO of Microbiotica, said: “It is rewarding for our team to achieve this recognition in the first year. Being selected for this award by our peers is a great endorsement of the strength of Microbiotica’s science and the progress made by its talented team.”

Microbiotica Shortlisted for 2017 OBN Awards ‘Best Start-up Biotech Company’

/in /by

Cambridge, UK, 9 August 2017 – Microbiotica, a leading player in microbiome-based therapeutics, is delighted to be announced that it has been selected as a finalist in the ‘Best Start-up Biotech Company’ category of the OBN Awards 2017.

Being selected for the shortlist recognises Microbiotica’s commercial potential in the fast growing microbiome space, reflecting its innovative understanding of the gut microbiome and the therapeutic potential to address a host of disorders through microbial targets.

In 2016, Microbiotica was created with £8m funding from Cambridge Innovation Capital and IP Group to commercialise the groundbreaking research of the Wellcome Trust Sanger Institute.

The finalist will be selected on the following criteria: formed for less than two years, has raised substantial financial support (£1m-£20m), is developing novel and disruptive products and has proof of financing raised and ongoing deals in the pipeline, with evidence of a commercialisation strategy.

The winners for all eight categories will be announced at the awards evening on Tuesday 5 October 2017 at the OBN Annual Awards Ceremony at Oxford Town Hall.

Microbiotica Wins One Nucleus Summer BioNewsRound Award

/in /by

Cambridge, UK, 13 July 2017 – Microbiotica, a leading player in microbiome-based therapeutics, is pleased to announce that it was voted as the winner of the Summer 2017 BioNewsRound Award at the One Nucleus event held ahead of the Annual On Helix conference in Cambridge.

Microbiotica won the award based on the prospects for the company, its reflection on innovation in the UK sector and its potential to bring benefits to patients.  Microbiotica was launched at the end of 2016 as the newest spin-out company from the UK’s world-renowned Wellcome Trust Sanger Institute with £8m funding from Cambridge Innovation Capital and IP Group. Each of 10 companies shortlisted for the Award presented to the audience which voted for their choice.

Mike Romanos, CEO of Microbiotica, said: “As a relatively new company it’s encouraging that our potential is already being recognised. Microbiotica was formed on world-class human microbiome research and we are looking forward to driving forward the discovery and development of novel microbiome-based therapeutics and biomarkers using this science.”

Harriet Fear, CEO of One Nucleus, said: “Choosing the 10 finalists from the many entries was tough. It was interesting that three of the finalists were in the microbiome space, reflecting the growing interest and huge potential in the area. Microbiotica was a worthy winner and it was great that they were presented with the award at our event held on the Wellcome Trust Genome Campus.“

Microbiotica Shortlisted for Biotech and Money’s ‘Life Science Spin-out of the Year’

/in /by

Cambridge, UK, 26 June 2017

Microbiotica, a leading player in microbiome-based therapeutics, is delighted to announce that it has been shortlisted for the ‘Life Science Spin-out of the Year’ category of the Biotech and Money 2017 Awards.

Microbiotica was selected as a shortlisted finalist for its success as the newest spin-out company from the UK’s world-reknowned Wellcome Trust Sanger Institute, Cambridge, with £8m funding from Cambridge Innovation Capital and IP Group. The judges recognised the Company’s leadership position in understanding how the microbiome can be used to not only develop new therapeutics for a range of diseases but also how to stratify patients according to their microbial profile, identify links with disease and exploit its full potential for human healthcare.

Voting is now open. The winners in each category are determined 50% by this online voting and 50% by a live vote on the night of the Awards dinner, which is held in London on 14 September.

Microbiotica to Present at Microbiome Drug Development Summit

/in /by

27-29 June 2017, Boston

Cambridge, UK, 20 June 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that its Chief Scientific Officer Dr Trevor Lawley will present at this year’s Microbiome Drug Development Summit, 27-29 June in Boston.

Dr Lawley’s talk ‘Culturing the “unculturable” to harness the therapeutic potential of the human intestinal microbiome’ will take place at 9.00am on Wednesday 28 June. The presentation will focus on his pioneering work that allows culturing, genomic and functional characterisation of the majority of the intestinal microbiota.

Microbiotica, which was spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Lawley and is focused on microbiome biology and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics. Cambridge Innovation Capital and IP Group co-invested £8 million into the start-up.

Dr Mike Romanos, CEO of Microbiotica, said: “Over the past decade there has been a groundswell of research demonstrating how pivotal the human microbiome is to health and disease. Trevor’s research at the Sanger Institute has transformed our ability to culture, sequence and characterise bacteria associated with biological phenotypes, opening up new avenues for therapeutic and biomarker discovery, which Microbiotica is translating and commercialising.”

The Microbiome Drug Development Summit is a meeting dedicated to accelerating the discovery, clinical development and commercialisation of a new generation of microbiome-based therapeutics. This year’s event runs from 27-29 June and will be held at Aloft Boston Seaport, Boston.

Microbiotica Appoints John Shields as Non-Executive Director

/in /by

Microbiotica, the spin-out company from the UK’s Wellcome Trust Sanger Institute (Sanger Institute), is pleased to announce the appointment of Dr John Shields as a non-executive director representing the Sanger Institute.

Dr Shields has extensive operational and investment experience in the biotechnology sector and is currently a member of the Sanger Institute Translation Committee, the Crick Institute Translation Advisory Group and the Medical Research Council’s Translational Research Group. He serves on a number of biotechnology company boards and is an adviser to several venture capital groups. Previously, he was an adviser to Abingworth Management, the life-sciences focused venture capital group, and has also worked in the pharma and biotech industry, initially at Glaxo and then as SVP Research for Cantab Pharmaceuticals.

Mike Romanos, Chief Executive Officer of Microbiotica, commented: “We are delighted to welcome John to Microbiotica’s Board. His experience in the translation of innovative science will bring invaluable insights to the company as we work to commercialise ground-breaking research into the role of the human microbiome in health and disease, and its application to medicine. His appointment is a welcome and tangible demonstration of our ongoing close link with the Sanger Institute, and I am sure he will make an immediate and important contribution to the team.”

Dr Shields commented: “Microbiotica is an immensely interesting organisation with, I believe, significant potential to apply its understanding of the role of human gut microbiome in health and disease to develop bacteriotherapies. I am looking forward to helping the team realise the enormous opportunity which is emerging from our increased knowledge of the role of the microbiome and to offering a new approach for treating diseases for which conventional treatments have been inadequate.”

Dr Shields joins existing Microbiotica Board members Mike Romanos, CEO, and Trevor Lawley, Chief Scientific Officer, along with Sam Williams, Head of Biotech at IP Group plc, and Robert Tansley, Investment Director at Cambridge Innovation Capital plc.

– ENDS –

Notes about Microbiotica

  • Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute.
  • Microbiotica’s founders are Mike Romanos, Trevor Lawley and Gordon Dougan, FRS.
  • CIC and IP Group are co-investors in Microbiotica, with a £4m contribution from each party to provide total initial funding of £8m.
  • Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute.